Physician profile
David Wendt
NPI 1285633545
$3,303.27
in general payments reported to CMS, 2019-2025
24 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2022: $85.91 · 2023: $549 · 2024: $1,470 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998 · Travel and Lodging: $94.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,998.44 |
| Travel and Lodging | $94.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $680.09 | 2023-2025 | Watchman Access System, Watchman Flx, Bodyguardian |
| Novartis Pharmaceuticals Corporation | $650.23 | 2023-2025 | |
| Amgen INC. | $435.02 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $174.22 | 2023-2025 | Farxiga, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $148.90 | 2025 | |
| Baxter Healthcare | $140.67 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $127.92 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $125.31 | 2023-2025 | Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.65 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $112.11 | 2024 | Mounjaro |
| Heartflow, INC. | $87.56 | 2025 | |
| Abbott Laboratories | $78.11 | 2024-2025 | Amplatzer Amulet, Merlin@Home, Gallant |
| Merck Sharp & Dohme LLC | $65.34 | 2023-2025 | Winrevair, Verquvo |
| Novo Nordisk INC | $62.09 | 2023-2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $53.33 | 2024-2025 | Camzyos, Eliquis |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $38.06 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $36.73 | 2022 | |
| Inspire Medical Systems, INC. | $34.98 | 2025 | Inspire |
| Vital Connect, INC | $32.56 | 2024 | Vitalpatch Rtm |
| United Therapeutics Corporation | $31.37 | 2025 | Tyvaso |
| Kiniksa Pharmaceuticals International, Plc | $19.64 | 2024 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $16.89 | 2024 | Uptravi, Opsumit |
| Biosense Webster, INC. | $14.38 | 2025 | Carto 3 |
| Philips North America LLC | $14.11 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wendt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.